Well-designed clinical trials with depression as a primary outcome measure are needed to establish whether GLP-1 agonists have genuine antidepressant properties independent of their metabolic effects
This represents the best-quality clinical evidence for DSIP, though the sample size was small Multi-species animal data -- DSIP has demonstrated sleep-promoting effects in rabbits, mice, rats, cats, and humans Stress modulation -- DSIP suppresses stress-induced cortisol and ACTH rises, potentially relevant for stress-related insomnia Opioid and alcohol withdrawal -- small studies explored DSIP as an adjunct in withdrawal management 2024 fusion peptide study -- published in Frontiers in Pharmacology, research on DSIP-BBB fusion peptides in insomnia mouse models represents renewed interest in DSIP Important limitations of DSIP's clinical evidence: Most studies are from the 1980s-1990s, conducted before modern polysomnography and sleep study methodology were standardized Sample sizes are consistently small Results are inconsistent across studies -- some show clear sleep effects while others do not No large-scale, placebo-controlled RCTs have been conducted Publication bias (positive results more likely published) may inflate the apparent evidence Side Effects Comparison# Cortistatin Side Effects# No human safety data exists
Together, these mechanisms produce the 15-20% average body weight loss seen in the clinical trials, results that changed what the medical community considered possible with pharmacological intervention
In addition to these primary functions, the meniscus also lubricates the knee joint
Available at: (Accessed on 5th January 2026)
